MYFORTIC Gastro-resistant tablet Ref.[9668] Active ingredients: Mycophenolic acid

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2020  Publisher: Novartis Pharmaceuticals UK Limited, 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ, United Kingdom

Product name and form

Myfortic 180 mg gastro-resistant tablets.

Myfortic 360 mg gastro-resistant tablets.

Pharmaceutical Form

Gastro-resistant tablet.

180mg: Lime green, film-coated round tablet, with bevelled edges and the imprint (debossing) “C” on one side.

360mg: Pale orange red film-coated ovaloid tablet, with imprint (debossing) “CT” on one side.

Qualitative and quantitative composition

Each gastro-resistant tablet contains 180 mg or 360 mg mycophenolic acid (as mycophenolate sodium).

Excipient with known effect: Lactose, anhydrous: 45 mg or 90 mg per tablet.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Mycophenolic acid

Mycophenolic acid is a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase, and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Mycophenolic acid has more potent cytostatic effects on lymphocytes than on other cells and is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants.

List of Excipients

Core:

Maize starch
Povidone
Crospovidone
Lactose, anhydrous
Silica, colloidal anhydrous
Magnesium stearate

Coating:

Hypromellose phthalate
Titanium dioxide (E171)
Iron oxide yellow (E172)
Indigo Carmine (E132) (180mg only)
Iron oxide red (E172) (360mg only)

Pack sizes and marketing

The tablets are packed in polyamide/aluminium/PVC/aluminium blister packs of 10 tablets per blister in quantities of 20, (180mg only), 50, 100, 120 or 250 tablets per carton.

Not all pack sizes may be marketed.

Marketing authorization holder

Novartis Pharmaceuticals UK Limited, 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ, United Kingdom

Marketing authorization dates and numbers

Myfortic 180mg gastro-resistant tablets: PL 00101/0664
Myfortic 360mg gastro-resistant tablets: PL 00101/0665

Date of first authorisation: 5 July 2004
Date of latest renewal: 10 October 2008

Drugs

Drug Countries
MYFORTIC Austria, Australia, Brazil, Canada, Cyprus, Germany, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Malta, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States, South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.